Eris Lifesciences gets nod to acquire 30% stake in Swiss Parenterals

25 Nov 2025 Evaluate

Eris Lifesciences has received approval for acquisition of 30% of the total share capital of Swiss Parenterals, a subsidiary of the company. With the objective of fully consolidating its position, enhancing operational synergy, and strengthening its long-term strategic presence, the company now proposes to acquire 100% ownership of Swiss. This consolidation is expected to provide complete managerial control, enable full financial consolidation, improve cost efficiencies, streamline governance, and contribute to enhanced shareholder value.

The proposed transaction is expected to complete tentatively prior to March 31, 2026. The Board of Directors of the company, in their meeting held on November 24, 2025, has approved the same.

Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.


Eris Lifesciences Share Price

1552.75 -5.65 (-0.36%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×